. 2020 Sep 22;79(12):1588–1599. doi: 10.1136/annrheumdis-2020-217646

Table 1.

Summary of the patient characteristics

Complete cohort	Sjögren’s syndrome n=83	NSCS n=65	Healthy donors n=12
Gender, F/M	75/8	57/8	11/1
Age in years mean	54 [55] (14.0)	55 [56] (13.3)	43 [44] (7.4)
[median] (SD)	54 [55] (14.0)	55 [56] (13.3)	43 [44] (7.4)
Primary/ Secondary Sjogren’s syndrome	74/9
Disease duration in years	5.9 [3] (6.0)	5.1 [3] (5.6)
Mean [median] (SD)	5.9 [3] (6.0)	5.1 [3] (5.6)
ESSDAI	5.5 [5] (4.9)	n/a
Mean [median] (SD)	5.5 [5] (4.9)	n/a
Anti-Ro	59%	0%
Positive of total	59%	0%
Anti-La	35%	0%
Positive of total	35%	0%
Rheumatoid factor	51%	11%
Positive of total	51%	11%
Serum IgG (g/L)	15.4 [14.0] (5.8)	11.0 [11.1] (3.7)
Mean [median] (SD)	15.4 [14.0] (5.8)	11.0 [11.1] (3.7)
Serum IgA (g/L)	2.9 [2.3] (1.8)	2.8 [2.5] (2.4)
Mean [median] (SD)	2.9 [2.3] (1.8)	2.8 [2.5] (2.4)
Serum IgM (g/L)	1.5 [1.1] (2.0)	1.3 [1.1] (0.7)
Mean [median] (SD)	1.5 [1.1] (2.0)	1.3 [1.1] (0.7)
Serum C3 (g/L)	1.2 [1.2] (0.3)	1.5 [1.3] (1.3)
Mean [median] (SD)	1.2 [1.2] (0.3)	1.5 [1.3] (1.3)
Serum C4 (g/L)	0.2 [0.2] (0.1)	0.3 [0.3] (0.1)
Mean [median] (SD)	0.2 [0.2] (0.1)	0.3 [0.3] (0.1)
Lymphocytes count (x10⁹/L)	1.6 [1.5] (0.6)	2.2 [2.1] (0.8)
Mean [median] (SD)	1.6 [1.5] (0.6)	2.2 [2.1] (0.8)
Treatments
Hydroxychloroquine csDMARDs*	35/83 8/83
Steroids	5/83

*csDMARDs other than hydroxychloroquine.

csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; ESSDAI, EULAR Sjogren's syndrome disease activity index; NSCA, non-specific chronic sialadenitis.